Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P48729

UPID:
KC1A_HUMAN

ALTERNATIVE NAMES:
CK1

ALTERNATIVE UPACC:
P48729; D3DQG0; D3DQG1; Q4JJA0; Q5U046; Q5U047; Q6FGA2; Q71TU5; Q96HD2; Q9UDK3

BACKGROUND:
The enzyme Casein kinase I isoform alpha, also known as CK1, with the unique identifier P48729, functions by phosphorylating a wide array of proteins, including those involved in Wnt signaling and the potential phosphorylation of PER1 and PER2. Its activity is crucial for the disassembly of the keratin cytoskeleton, affecting epithelial cell migration, and it plays a role in chromosome segregation during mitosis. Additionally, CK1 acts as an inhibitor of NLRP3 inflammasome assembly, underscoring its regulatory capacity in immune responses.

THERAPEUTIC SIGNIFICANCE:
The exploration of Casein kinase I isoform alpha's functions offers a promising avenue for the development of novel therapeutic interventions. By elucidating CK1's role in critical cellular pathways such as Wnt signaling and NLRP3 inflammasome regulation, researchers can identify new targets for the treatment of related pathologies, paving the way for innovative drug development.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.